Vera Therapeutics, Inc.
VERA · Price history
Price at last available close
$30.94
−$1.44 (-4.45%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Vera Therapeutics, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy.
How they make money
Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with immunological diseases. The company currently operates as a research and development entity and has not yet generated revenue from product sales, relying instead on capital raises and strategic collaborations to fund its operations.
Products & services
The company's primary product candidate is atacicept, a fusion protein targeting BAFF and APRIL for the treatment of IgA nephropathy and other autoimmune diseases. It is also developing VT-109, a next-generation fusion protein for B-cell-mediated diseases.
Brands & revenue mix
Lead clinical-stage product candidate for IgA nephropathy.
Separate brand revenue is not available in this research.Source
Preclinical-stage fusion protein candidate.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
- Healthcare providers and patients with immunological diseasesSource
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Stanford University — A license agreement to acquire global rights to VT-109, a novel fusion protein targeting BAFF and APRIL for B-cell-mediated diseases.Source
Competitors
- RemeGen — Developer of telitacicept, a biologic fusion protein that competes in the space of B-cell-mediated disease therapeutics.Source
Strengths
- Clinical progress of atacicept in IgA nephropathySource
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
18
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
28
Poor
Financial Strength
15
Business Quality / Moat
50
Management
0
Growth Quality
63
Risk / Durability
19
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
32
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
40/100
Building Historical Record
Model Score 40/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for VERA
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can VERA fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does VERA's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for VERA to reach sustainable profitability?
- •What future growth or profitability would be needed to justify VERA's current valuation?
- •What does the current none warning mean for the reliability or interpretation of VERA's score?
Essential Investment Snapshot
Wall Street Score
18
Opportunity Score
32
Market Cap
$2.23B
P/E Ratio
-4.8
EPS
$-5.86
52-Week High
$56.05
52-Week Low
$23.05
Beta
0.95
Analyst Target
$84.00
Shares Outstanding
64.2M
Total Revenue
$0
Total Debt
$75.2M
Dividend
No current dividend
Liquidation Value / Share
$6.35
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for VERA
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-41.9x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on VERA.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Clinical progress of atacicept in IgA nephropathy.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on third-party manufacturers and clinical trial success.
- −History of operating losses and potential need for additional capital.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
4 historical score records availablePrevious Score
18
Oct 23, 2026
Change
Unchanged
Current Score
18
Oct 26, 2026
Category Changes
VERA score was unchanged.
Projected Score
Projected Score
22
Projected Change
+4.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 4.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$30.94
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· |
| Research & Development | $261.9M | $215.3M | $126.2M | $78.2M | ···· | ···· | ···· | ···· |
| SG&A Expenses | $153.9M | $100.2M | $41.0M | $23.8M | ···· | ···· | ···· | ···· |
| Operating Expenses | $415.8M | $315.5M | $167.2M | $102.0M | ···· | ···· | ···· | ···· |
| EBITDA | -$393.8M | -$291.6M | -$144.4M | -$92.2M | ···· | ···· | ···· | ···· |
| Operating Income | -$415.8M | -$315.5M | -$167.2M | -$102.0M | ···· | ···· | ···· | ···· |
| Interest Expense | $7.5M | $7.5M | $7.6M | $3.8M | ···· | ···· | ···· | ···· |
| Income Before Tax | -$401.9M | -$299.6M | -$152.1M | -$96.0M | ···· | ···· | ···· | ···· |
| Income Tax Expense | $1K | $1K | $1K | $1K | ···· | ···· | ···· | ···· |
| Net Income | -$401.9M | -$299.6M | -$152.1M | -$96.0M | ···· | ···· | ···· | ···· |
| Basic EPS | $-5.86 | $-4.66 | $-2.75 | $-2.25 | ···· | ···· | ···· | ···· |
| Basic Shares | 71.84M | 64.23M | 55.33M | 42.71M | ···· | ···· | ···· | ···· |
| Diluted Shares | 71.84M | 64.23M | 55.33M | 42.71M | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$1.52
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-3.0%
Cash Change
-0.5%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included EPS growth, debt levels. Pressure indicators included cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS increased 26.7%. Cash declined 0.5%. Total debt declined 3.0%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
4 historical recordsHistorical Score Chart
3 of 4 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results
Vera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript
Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
Vera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
Rumor Mill · VERA
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial